COMPOSITIONS AND METHODS FOR INHIBITING KRAS FOR THE TREATMENT OF DISEASE
A peptide-polynucleotide complex effectively inhibits KRAS expression in cancer cells by delivering siRNA, addressing the inefficiencies and cytotoxicity of existing methods, thereby offering a therapeutic option for KRAS-related diseases.
BR112025016981A2Pending Publication Date: 2026-08-04ALTAMIRA THERAPEUTICS AG
0 Cites 0 Cited by
Patent Information
- Application Number
- BR112025016981
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-23
- Filing Date
- 2024-02-21
- Publication Date
- 2026-08-04
AI Technical Summary
Technical Problem
Current treatments for KRAS-related diseases, such as cancer, lack effective methods to inhibit the KRAS gene, which is commonly mutated and drives oncogenic events, and existing delivery systems for siRNA are cytotoxic and inefficient.
Method used
A peptide-polynucleotide complex is developed, comprising a peptide with specific amino acid sequences and a small interfering RNA (siRNA) targeting KRAS mRNA, designed to be non-lytic and non-cytotoxic, which efficiently delivers the siRNA into cells to inhibit KRAS expression.
Benefits of technology
The complex effectively knocks down KRAS expression in various cell lines, including those with mutations, reducing cancer cell viability and providing a therapeutic approach for KRAS-related diseases without significant cytotoxicity.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure provides pharmaceutical compositions comprising a peptide- polynucleotide complex, wherein the peptide comprises an amino acid sequence with at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; and wherein the polynucleotide is a small interfering RNA (siRNA) targeting human KRAS mRNA, wherein the target sequence of human KRAS mRNA does not encode G12, G13, or Q61 with reference to SEQ ID NO: 4 or a mutant amino acid at position 12, 13, or 61 with reference to SEQ ID NO: 4.
Need to check novelty before this filing date? Find Prior Art